Nanexa: Novo deal in place, next project in focus - Emergers
Bildkälla: Stockfoto

Nanexa: Novo deal in place, next project in focus - Emergers

The EUR 20m upfront from Nanexa’s breakthrough deal with Novo in Q3 turned out to be larger than the EUR 15m we initially expected, and payment has now been confirmed as received after quarter-end, materially strengthening Nanexa’s financial position.

The global, exclusive PharmaShell agreement covers up to five peptide-based programmes within obesity, type 2 diabetes and other cardiometabolic diseases, targeting monthly or quarterly dosing. Alongside its work with Novo and Moderna, Nanexa is now in the process of selecting its next proprietary development project, with an announcement expected early next year.

We have made minor adjustments to our valuation model following the report, while retaining our development timelines and probabilities of success. Our updated risk-adjusted valuation puts the Novo agreement at about SEK 14 per share and the total sum-of-the-parts at approximately SEK 16.3 (16.6).

The upfront provides financial flexibility, but most of the value still depends on future milestones and royalties. Clinical progress, the undisclosed royalty terms and further platform agreements therefore remain the main drivers of the investment case.
Börsvärldens nyhetsbrev